Industry
Featured experience
Amgen $28.5 billion Horizon Therapeutics acquisition financing
We advised the lender parties on the financing
Forbion European Acquisition $138 million combination with enGene
We advised Forbion European Acquisition on its de-SPAC transaction
Bausch + Lomb $630 million IPO
We are advising Bausch Health on the separation of its eye health business into a new public company, Bausch + Lomb
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Tempus AI $410 million IPO
The stock is listed on the Nasdaq Global Select Market
ProKidney $140 million follow-on offerings
We advised ProKidney on the offering
Royalty Pharma $1.5 billion senior notes offering
We advised Royalty Pharma on its investment-grade notes offering
Medtronic €3 billion notes offering
The notes are due 2029, 2036, 2043 and 2053
Elevance Health $2.6 billion senior notes offering
The investment-grade notes are due 2029, 2034 and 2054
Merck €3.4 billion notes offering
The investment-grade notes offering consists of four tranches
Perspective Therapeutics $80 million offering
The stock is listed on the NYSE American
Asahi Kasei $1.1 billion offer to acquire Calliditas Therapeutics
We are advising Lazard as financial adviser to Calliditas on the transaction
Nordson $800 million acquisition of Atrion
We are advising Nordson on the acquisition
AC Immune exclusive option and license agreement with Takeda Pharmaceuticals
We advised AC Immune on the transaction